182 related articles for article (PubMed ID: 37916958)
1. Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.
Varkaris A; Fece de la Cruz F; Martin EE; Norden BL; Chevalier N; Kehlmann AM; Leshchiner I; Barnes H; Ehnstrom S; Stavridi AM; Yuan X; Kim JS; Ellis H; Papatheodoridi A; Gunaydin H; Danysh BP; Parida L; Sanidas I; Ji Y; Lau K; Wulf GM; Bardia A; Spring LM; Isakoff SJ; Lennerz JK; Del Vecchio K; Pierce L; Pazolli E; Getz G; Corcoran RB; Juric D
Cancer Discov; 2024 Feb; 14(2):227-239. PubMed ID: 37916958
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
Varkaris A; Pazolli E; Gunaydin H; Wang Q; Pierce L; Boezio AA; Bulku A; DiPietro L; Fridrich C; Frost A; Giordanetto F; Hamilton EP; Harris K; Holliday M; Hunter TL; Iskandar A; Ji Y; Larivée A; LaRochelle JR; Lescarbeau A; Llambi F; Lormil B; Mader MM; Mar BG; Martin I; McLean TH; Michelsen K; Pechersky Y; Puente-Poushnejad E; Raynor K; Rogala D; Samadani R; Schram AM; Shortsleeves K; Swaminathan S; Tajmir S; Tan G; Tang Y; Valverde R; Wehrenberg B; Wilbur J; Williams BR; Zeng H; Zhang H; Walters WP; Wolf BB; Shaw DE; Bergstrom DA; Watters J; Fraser JS; Fortin PD; Kipp DR
Cancer Discov; 2024 Feb; 14(2):240-257. PubMed ID: 37916956
[TBL] [Abstract][Full Text] [Related]
3. STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts.
Buckbinder L; St Jean DJ; Tieu T; Ladd B; Hilbert B; Wang W; Alltucker JT; Manimala S; Kryukov GV; Brooijmans N; Dowdell G; Jonsson P; Huff M; Guzman-Perez A; Jackson EL; Goncalves MD; Stuart DD
Cancer Discov; 2023 Nov; 13(11):2432-2447. PubMed ID: 37623743
[TBL] [Abstract][Full Text] [Related]
4. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
[TBL] [Abstract][Full Text] [Related]
5. Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP.
Menteş M; Karakuzulu BB; Uçar GB; Yandım C
Comput Biol Chem; 2022 Aug; 99():107726. PubMed ID: 35842959
[TBL] [Abstract][Full Text] [Related]
6. Genomic Alterations in
Cai Y; Xu G; Wu F; Michelini F; Chan C; Qu X; Selenica P; Ladewig E; Castel P; Cheng Y; Zhao A; Jhaveri K; Toska E; Jimenez M; Jacquet A; Tran-Dien A; Andre F; Chandarlapaty S; Reis-Filho JS; Razavi P; Scaltriti M
Cancer Res; 2021 May; 81(9):2470-2480. PubMed ID: 33685991
[TBL] [Abstract][Full Text] [Related]
7. Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer.
Kaklamani VG; Richardson AL; Arteaga CL
Oncologist; 2019 Mar; 24(3):305-312. PubMed ID: 30651399
[TBL] [Abstract][Full Text] [Related]
8. Alpelisib for
André F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo HS; Iwata H; Conte P; Mayer IA; Kaufman B; Yamashita T; Lu YS; Inoue K; Takahashi M; Pápai Z; Longin AS; Mills D; Wilke C; Hirawat S; Juric D;
N Engl J Med; 2019 May; 380(20):1929-1940. PubMed ID: 31091374
[TBL] [Abstract][Full Text] [Related]
9. N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kα inhibition in breast cancer.
Auf der Maur P; Trefny MP; Baumann Z; Vulin M; Correia AL; Diepenbruck M; Kramer N; Volkmann K; Preca BT; Ramos P; Leroy C; Eichlisberger T; Buczak K; Zilli F; Okamoto R; Rad R; Jensen MR; Fritsch C; Zippelius A; Stadler MB; Bentires-Alj M
Cell Rep Med; 2023 Apr; 4(4):101002. PubMed ID: 37044095
[TBL] [Abstract][Full Text] [Related]
10. Precision Targeting of Mutant PI3Kα.
Gong GQ; Vanhaesebroeck B
Cancer Discov; 2024 Feb; 14(2):204-207. PubMed ID: 38327193
[TBL] [Abstract][Full Text] [Related]
11. Double
Vasan N; Razavi P; Johnson JL; Shao H; Shah H; Antoine A; Ladewig E; Gorelick A; Lin TY; Toska E; Xu G; Kazmi A; Chang MT; Taylor BS; Dickler MN; Jhaveri K; Chandarlapaty S; Rabadan R; Reznik E; Smith ML; Sebra R; Schimmoller F; Wilson TR; Friedman LS; Cantley LC; Scaltriti M; Baselga J
Science; 2019 Nov; 366(6466):714-723. PubMed ID: 31699932
[TBL] [Abstract][Full Text] [Related]
12. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
André F; Ciruelos EM; Juric D; Loibl S; Campone M; Mayer IA; Rubovszky G; Yamashita T; Kaufman B; Lu YS; Inoue K; Pápai Z; Takahashi M; Ghaznawi F; Mills D; Kaper M; Miller M; Conte PF; Iwata H; Rugo HS
Ann Oncol; 2021 Feb; 32(2):208-217. PubMed ID: 33246021
[TBL] [Abstract][Full Text] [Related]
13. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
[TBL] [Abstract][Full Text] [Related]
14. CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer.
Stanland LJ; Ang HX; Hoj JP; Chu Y; Tan P; Wood KC; Luftig MA
Mol Cancer Res; 2023 Nov; 21(11):1148-1162. PubMed ID: 37493631
[TBL] [Abstract][Full Text] [Related]
15. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.
Bertho M; Patsouris A; Augereau P; Robert M; Frenel JS; Blonz C; Campone M
Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):139-152. PubMed ID: 33213227
[No Abstract] [Full Text] [Related]
17. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Rugo HS; Lerebours F; Ciruelos E; Drullinsky P; Ruiz-Borrego M; Neven P; Park YH; Prat A; Bachelot T; Juric D; Turner N; Sophos N; Zarate JP; Arce C; Shen YM; Turner S; Kanakamedala H; Hsu WC; Chia S
Lancet Oncol; 2021 Apr; 22(4):489-498. PubMed ID: 33794206
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Xing Y; Lin NU; Maurer MA; Chen H; Mahvash A; Sahin A; Akcakanat A; Li Y; Abramson V; Litton J; Chavez-MacGregor M; Valero V; Piha-Paul SA; Hong D; Do KA; Tarco E; Riall D; Eterovic AK; Wulf GM; Cantley LC; Mills GB; Doyle LA; Winer E; Hortobagyi GN; Gonzalez-Angulo AM; Meric-Bernstam F
Breast Cancer Res; 2019 Jul; 21(1):78. PubMed ID: 31277699
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
20. The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer.
VanLandingham NK; Nazarenko A; Grandis JR; Johnson DE
Adv Biol Regul; 2023 Jan; 87():100934. PubMed ID: 36402737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
